Pulmonary Arterial Hypertension: Navigating the Treatment Paradigm, Emerging Therapies, and Health Care System Impact : Episode 10
Opinion
Video
FDA Approves Sotatercept for Pulmonary Arterial Hypertension
Author(s):
Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.
EP: 1.Evolving Guidelines for PAH Treatment
EP: 2.New Therapeutic Frontiers in PAH
EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management
EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
EP: 5.Breaking Down the PAH Cost Burden
EP: 6.A New Era in PAH Treatment?
EP: 7.Clinical Evidence for Emerging PAH Therapies
EP: 8.Integrating New PAH Therapies into Clinical Practice
EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes
Now Viewing
EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension
EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH
EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
EP: 13.Optimizing PAH Care Delivery for Better Outcomes
EP: 14.Addressing Unmet Needs in the PAH Landscape
Video content above is prompted by the following question(s):
- What is the mechanism of action for the recent FDA-approved drug sotatercept and how does it differ from existing pulmonary arterial hypertension (PAH) therapies?
- Given that sotatercept is currently approved as an add-on therapy, what potential cost implications should payers and health systems consider?
- Is sotatercept being studied as a foundational therapy for PAH? If so, what potential advantages or disadvantages could it offer compared to existing foundational therapies?
Related Videos
Related Content
